- Home
- MNPR vs AWP Comparison
MNPR vs AWP Comparison
Compare MNPR & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | AWP |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 348.9M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MNPR | AWP |
|---|---|---|
| Price | $59.35 | $11.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $107.00 | N/A |
| AVG Volume (30 Days) | ★ 149.2K | 110.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.48% |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.18 | $3.78 |
| 52 Week High | $105.00 | $12.71 |
Technical Indicators
Market Signals| Indicator | MNPR | AWP |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 55.84 |
| Support Level | $56.02 | $11.48 |
| Resistance Level | $60.67 | $12.03 |
| Average True Range (ATR) | 3.50 | 0.15 |
| MACD | -0.56 | 0.02 |
| Stochastic Oscillator | 15.69 | 86.79 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.